National Institutes of Health

GreenMark Biomedical Inc. is a healthcare company focused on developing minimally invasive technologies utilizing biopolymer nanoparticles derived from natural starch. Founded in 2016 and based in East Lansing, Michigan, with a laboratory in Ann Arbor, the company aims to enhance diagnostic and treatment capabilities in dentistry and oncology. GreenMark offers a mouth rinse product that highlights cavities and early-stage lesions, allowing dentists to accurately assess dental issues using standard dental curing lamps. Additionally, the company is working on medical applications that target anti-cancer drug delivery, facilitating site-specific treatments. Through its innovative approach, GreenMark Biomedical seeks to provide effective health-based solutions that improve patient care.

Lucid Diagnostics is a commercial-stage, cancer-prevention medical diagnostics company. Lucid focuses on patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard Esophageal DNA Test is performed on samples collected in a brief noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, a diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients.

Myosin Therapeutics is a privately-held biopharmaceutical company dedicated to developing innovative medications for central nervous system (CNS) disorders and other significant unmet medical needs. The company focuses on creating novel drugs that target cellular motor proteins, which are essential molecular machines that convert energy into mechanical work within cells. This unique approach enables the potential treatment of various disease states, including cancer. By harnessing the capabilities of these motor proteins, Myosin Therapeutics aims to advance therapeutic options and improve patient outcomes in challenging medical areas.

Vast Therapeutics is a preclinical-stage pharmaceutical company based in Durham, North Carolina, focused on developing inhalable treatments for antibiotic-resistant pathogens affecting patients with cystic fibrosis and other respiratory diseases. Founded in 2017 and originally known as Novoclem Therapeutics, the company aims to address chronic infections prevalent among the cystic fibrosis population. Vast Therapeutics operates as a subsidiary of KNOW Bio, LLC, and is dedicated to advancing innovative therapeutic solutions for individuals facing these challenging health conditions.

Sparian Biosciences is an early-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for the central nervous system (CNS). The firm focuses on creating unique medicines that target the brain, utilizing cutting-edge scientific approaches and novel drug discovery techniques. In addition to its core mission, Sparian is also developing a new analgesic aimed at addressing both acute and chronic pain, further emphasizing its commitment to advancing treatments for CNS-related conditions.

Brixton Biosciences is a clinical-stage life sciences company focused on developing innovative therapies for chronic and acute pain management. The company aims to address significant unmet needs in this area, which has traditionally relied on systemic medications. Its flagship product, Neural Ice™, is a drug-free injectable treatment designed to induce reversible inhibition of nerves, offering a non-addictive, locally targeted solution. This therapy provides patients with extended pain relief lasting from thirty to sixty days following a single injection, representing a significant advancement over current pain management methods.

Allyx Therapeutics, founded in 2018 and based in Durham, Connecticut, is a clinical-stage biotechnology company focused on developing disease-modifying treatments for Alzheimer's Disease. The company’s primary product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative drug aims to reverse neurodegeneration and offers a potential approach to preserve cognitive function in patients with Alzheimer's. By targeting the underlying mechanisms of the disease, Allyx Therapeutics strives to provide effective therapeutic solutions for those affected by neurodegenerative disorders.

CytoAgents, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, established in 2018. The company specializes in developing protein-based drugs aimed at treating viral infections, particularly influenza, and addressing life-threatening symptoms associated with Cytokine Release Syndrome (CRS). CRS is an overreaction of the immune system that results in systemic inflammation, often referred to as a cytokine storm. One of its primary products, GP1681, acts as an agonist of a G-protein coupled receptor, targeting the immune response in various medical conditions. CytoAgents focuses on creating treatments for multiple indications with significant unmet medical needs, including those arising from oncology CAR-T cell therapy, COVID-19, and respiratory epidemics, thereby providing healthcare professionals with innovative tools to manage patients experiencing severe immune reactions.

Resvita Bio is engaged in the development and manufacturing of engineered probiotics aimed at treating skin-related diseases, including chronic conditions and cancer. The company focuses on creating a versatile skin microbial platform utilizing synthetic biology and metabolic engineering. This innovative approach allows for the continuous delivery of therapies that alleviate inflammation, promote tissue regeneration, and eliminate harmful bacteria. By leveraging this technology, Resvita Bio aims to offer faster and more efficient treatment alternatives for individuals suffering from chronic skin diseases.

Cenna Biosciences focuses on the discovery and development of innovative drugs aimed at preventing and treating Alzheimer's disease. The company utilizes a proprietary technology that targets the underlying cause of the disease, specifically addressing the harmful accumulation of beta-amyloid (Aß) in the brains of affected individuals. Cenna has identified a novel target and is in the process of developing several lead peptide compounds as potential disease-modifying treatments for Alzheimer's.

Tiziana Life Sciences is a clinical-stage biotechnology company based in London, UK, focused on discovering and developing novel therapeutic molecules for oncology and immunology. The company's product pipeline includes Foralumab, a human anti-CD3 monoclonal antibody aimed at treating autoimmune and inflammatory diseases such as graft-versus-host disease and multiple sclerosis. Another key asset is Milciclib, an orally bioavailable small molecule that inhibits cyclin-dependent kinases and is currently undergoing phase II clinical trials for epithelial thymic carcinoma. Additionally, Tiziana is developing Anti IL-6r, a monoclonal antibody targeting interleukin-6 for severe COVID-19 cases, and StemPrintER, a multi-gene signature assay for estrogen-receptor positive breast cancer patients. Founded in 2013, Tiziana Life Sciences is dedicated to advancing innovative therapies for serious diseases, including neurodegenerative disorders and lung diseases.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

Precision Epigenomics, established in 2020 and based in Tucson, Arizona, specializes in molecular diagnostics for cancer. The company focuses on developing innovative molecular diagnostic assays, leveraging DNA methylation analysis, an epigenetic modification, to enhance cancer diagnosis and treatment. Their offerings aim to address unmet clinical needs, aiding clinicians in improved patient management.

Evoq Therapeutics is a company specializing in cancer immunotherapy and the treatment of autoimmune diseases. It employs a proprietary technology platform that features a NanoDisc, designed to deliver disease-specific immune modulators effectively. This innovative approach aims to restore immune tolerance, allowing the body to better manage conditions such as celiac disease, type one diabetes, lupus, pemphigus, Graves' disease, and rheumatoid arthritis. By targeting these diseases through its novel nanodisc-based therapy, Evoq Therapeutics seeks to improve the lives of individuals affected by autoimmune disorders and enhance the overall efficacy of treatment strategies in various pre-clinical models.

Unlocked Labs specializes in developing innovative probiotics aimed at addressing chronic health conditions by utilizing genetically optimized microbial strains. The company focuses on activating dormant microbial abilities to effectively digest compounds that can lead to health issues. Their first product targets the risk of kidney stones by breaking down stone-forming compounds derived from healthy foods like leafy vegetables. Unlocked Labs employs alternative regulatory pathways to expedite the availability of safe and effective probiotic solutions for consumers. By harnessing the natural detoxifying capabilities of symbiotic microbes, their products aim to reduce acid levels in the body, making them both affordable and accessible to a wide audience.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company based in Houston, Texas, that focuses on developing and commercializing T cell-based immunotherapies and peptide-based vaccines for hematological malignancies and solid tumors. The company’s MultiTAA technology enhances the effectiveness of non-engineered tumor-specific T cells, enabling them to target multiple tumor-associated antigens simultaneously. This approach aims to prevent immune escape and foster durable immunity. Marker Therapeutics offers autologous T cell therapies for conditions such as lymphoma and multiple myeloma, while also developing allogeneic T cell therapies for acute myeloid leukemia and acute lymphoblastic leukemia. Additionally, the company is advancing peptide-based vaccines, including TPIV100/110 and TPIV200, which are currently in Phase II clinical trials for treating breast and ovarian cancers, respectively.

Immunovia is a diagnostics company focused on the early detection of pancreatic cancer and other complex diseases. Utilizing its proprietary IMMray platform, which is based on antibody microarray analysis, Immunovia develops and commercializes innovative diagnostic tools. The company conducts clinical trials and validation studies to ensure the accuracy and reliability of its tests, collaborating with medical institutions and research centers worldwide. By concentrating on early detection, Immunovia aims to enhance the treatment and management of pancreatic cancer, thereby improving patient survival rates. The technology developed by Immunovia could also facilitate early detection strategies for other cancers and autoimmune diseases in the future.

Anebulo Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative treatments for individuals experiencing cannabinoid overdose and substance addiction. Its primary product candidate, ANEB-001, is designed to counteract the adverse effects of cannabinoid overdose within one hour of administration. Clinical trials have demonstrated that ANEB-001 is rapidly absorbed and well-tolerated by patients. Additionally, it has been observed to induce weight loss, an effect linked to its action as a central cannabinoid receptor type 1 antagonist. The company aims to address the wide range of symptoms associated with cannabinoid overdose, which can include profound sedation, anxiety, panic, and psychosis with hallucinations.

Matter Bio is a biotechnology company dedicated to preserving genome integrity and enhancing longevity through the preservation of DNA information. The company aims to address the critical issue of information loss in the genome by assembling a team of expert scientists and executives. By focusing on mutation reversal, Matter Bio seeks to empower patients with the potential to improve their health and extend their lifespan. Through its innovative research services, the company strives to advance the understanding and application of genetic preservation techniques.

Selsym Biotech is a biotechnology company focused on developing innovative therapies aimed at controlling bleeding in trauma and surgical situations. The company's flagship product, Hemostatic Healing Hydrogels (H3), offers a novel solution to address critical challenges in hemorrhage control, particularly in light of ongoing platelet supply shortages and limitations related to shelf life. By providing effective platelet-mimetic therapies, Selsym Biotech seeks to revolutionize the management of uncontrolled bleeding, enhancing outcomes for patients in emergency and surgical settings.

Cincinnati Children’s Hospital Medical Center is a leading institution dedicated to improving child health, attracting patients and families both regionally and internationally. Recognized for its expertise, the hospital serves as a referral center for complex surgical procedures and treatments for rare pediatric diseases. The center is committed to advancing pediatric medicine by discovering innovative and effective treatment methods, solidifying its reputation as one of the foremost facilities for pediatric care globally.

Lamassu Pharma is a biotech startup dedicated to addressing the significant unmet medical need for severe acute pancreatitis. The company is focused on developing a novel small molecule therapy that has shown promising preclinical results in significantly reducing both mortality and morbidity associated with this condition. This therapeutic candidate, developed by leading scientists at Mayo Clinic, aims to improve medical outcomes for patients suffering from acute pancreatitis. Lamassu Pharma is currently advancing the development of this compound through safety testing, preparing for future clinical trials with the ultimate goal of saving lives and enhancing treatment options for those affected by this serious disease.

Perspective Therapeutics is a medical technology and radiopharmaceutical company focused on innovative cancer treatment solutions. The company employs a proprietary technology that uses the alpha-emitting isotope 212Pb combined with specialized targeting peptides to deliver targeted radiation directly to cancer cells. This approach aims to enhance the effectiveness of treatments while minimizing side effects, reflecting the company's commitment to personalized and precise medicine in addressing patients' medical needs.

AcuraStem Inc is a biotechnology company, founded in 2016 and based in Monrovia, California, that focuses on developing a precision medicine platform aimed at addressing Amyotrophic Lateral Sclerosis (ALS). The company utilizes complex cellular models derived from ALS patients to evaluate disease progression and test existing FDA-approved therapeutics and their combinations. By employing advanced cellular reprogramming and artificial intelligence technologies, AcuraStem seeks to transform the standard of care for neurodegenerative diseases, enabling drug discovery companies to assess their therapeutic candidates more effectively. The team comprises experts, including PhDs, professors, and experienced professionals from the pharmaceutical industry, all dedicated to finding innovative treatments for this challenging health issue.

Orlance provides more effective therapeutic and preventive vaccines for a wide spectrum of viral targets.

Hillhurst Biopharmaceuticals specializes in developing innovative, liquid therapeutic gases for treating sickle cell disease. Their core technology enables the precise, oral delivery of low-dose carbon monoxide, targeting a protective cellular mechanism to reduce inflammation, prevent cell death, and inhibit hemoglobin polymerization. This approach addresses challenges associated with traditional inhaled gas therapies, such as caregiver exposure and imprecise dosing, ensuring accurate and safe administration.

Endomimetics is focused on developing advanced bio-nanometric coating technology aimed at enhancing medical care for patients with kidney diseases. The company's innovative stent coating technology is designed to closely mimic human tissue, which helps to minimize the need for additional surgeries and improves the longevity of the devices. By reducing complications associated with the implantation of foreign materials, Endomimetics' technology aims to provide better outcomes for patients, ultimately improving their overall quality of care in the management of kidney-related health issues.

Rational Vaccines is a preclinical stage company focused on developing innovative vaccines to combat herpes simplex virus and its related diseases. The company is dedicated to creating live-attenuated viral immunotherapeutic and prophylactic vaccine candidates that aim to reduce the transmission of the herpes virus and effectively manage symptoms associated with its reactivation. By harnessing rational engineering techniques, Rational Vaccines seeks to revolutionize the treatment, prevention, and diagnosis of herpes infections, ultimately improving the quality of life for those affected by these conditions.

Integral Molecular, Inc. is a biotechnology company based in Philadelphia, Pennsylvania, specializing in the development of innovative technologies to aid drug discovery for diseases such as cancer, HIV, and arthritis. The company offers the Lipoparticle technology, which facilitates the identification and optimization of drug candidates targeting integral membrane proteins. With over 20 years of experience in the field, Integral Molecular has supported more than 400 companies in their research efforts, medication discovery, and vaccine development. Its products play a crucial role throughout the drug discovery process, particularly in the development of antibodies and chemical compounds targeting challenging protein targets.

Clene Nanomedicine, established in 2012 and headquartered in Salt Lake City, Utah, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for neurodegenerative diseases. The company has pioneered a unique nanotechnology drug platform that enables the creation of orally-administered neurotherapeutic drugs. This technology, known as Clean-Surface Nanosuspension, produces clean-surface nanocrystal medicines and serves as a foundation for a pipeline of new drug candidates aimed at addressing various diseases with significant unmet medical needs. Clene Nanomedicine's primary focus areas include demyelinating disorders and oncology.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in New York, focused on developing radiotherapies for patients with cancer. The company's lead product candidate, Iomab-B, is undergoing a pivotal Phase III clinical trial as a conditioning agent for patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to bone marrow transplantation. Another key candidate, Actimab-A, is in Phase II trials targeting newly diagnosed acute myeloid leukemia in patients aged 60 and older. Additionally, Actinium is developing Actimab-M for penta-refractory multiple myeloma, currently in Phase I trials. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cancer cells, enhancing treatment efficacy while minimizing damage to healthy tissues. Actinium also collaborates with Astellas Pharma to advance its technology. Founded in 2000, Actinium Pharmaceuticals aims to address unmet medical needs in hematology through innovative therapeutic approaches.

Neurodon Corporation is focused on discovering and developing disease-modifying therapies for intractable diseases by addressing endoplasmic reticulum (ER) stress, a significant factor in cell dysfunction and death. The company's innovative approach utilizes first-in-class modulators to restore calcium levels in cells, enabling the creation of therapeutics for conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and diabetes. Founded in 2019 and based in Crown Point, Indiana, Neurodon has advanced two candidates into IND-enabling studies, with plans to commence clinical trials in 2025. The company has raised over $11 million through various funding sources, including grants and partnerships, and is currently seeking additional funding to support its upcoming clinical studies. Neurodon’s unique platform technology positions it as a leader in addressing diseases linked to ER stress, with no direct competitors targeting the same mechanism of action.

Omniose is an early-stage biotechnology company focused on developing advanced conjugate vaccines to combat infectious diseases. The company specializes in pneumococcal conjugate vaccines, aiming to offer broader protection against various bacterial strains. Utilizing proprietary bioconjugation technology, Omniose's approach eliminates reliance on synthetic chemistry techniques, allowing for the generation of polysaccharide-protein conjugate-based vaccines targeting multiple pathogens, including respiratory infections caused by Streptococcus pneumoniae. This innovative platform enhances the ability of healthcare professionals to effectively treat patients by providing more comprehensive vaccine options.

Base Pair Biotechnologies, Inc. specializes in the research, development, and discovery of aptamer affinity ligands. Founded in 2012 and based in Pearland, Texas, the company provides custom aptamer discovery and development services, as well as assay development services, and offers a catalog of aptamer projects. Its innovative platform integrates novel libraries and patented methods that enhance the multiplexing of the aptamer discovery process, along with effective screening and validation techniques. The company collaborates with various academic, commercial, and governmental institutions to create new tools and technologies across multiple sectors, including diagnostics, therapeutics, agriculture, and environmental testing. Base Pair Biotechnologies has been engaged in aptamer research since 2004 and has recently expanded its offerings to the commercial market, significantly improving the efficiency and cost-effectiveness of custom aptamer development.

South Rampart Pharma is a clinical-stage life science company dedicated to developing safe and effective pain relief alternatives. The company focuses on synthesizing and characterizing new non-opioid and non-liver toxic molecules that target pain signaling pathways in the brain's periaqueductal grey (PAG) region. Its lead candidate, SRP-001, has received U.S. FDA Fast Track designation for acute pain treatment. This candidate aims to influence pain-related genes through various biological pathways, including endocannabinoid signaling and mechanical nociception, providing a promising solution to mitigate the risks associated with traditional pain medications, particularly their potential for abuse.

Strykagen manufactures transforming diagnostics and therapeutics for life-threatening rare muscle diseases.

Greenstone Biosciences is a drug discovery platform focused on accelerating the development of effective therapies for patients with urgent unmet medical needs. The company leverages advanced technologies, including artificial intelligence and human-induced pluripotent stem cells, to transform the traditional drug discovery process. By integrating these innovative approaches, Greenstone aims to streamline what is typically a slow and high-failure endeavor into a more rapid and efficient system, ultimately delivering safe and effective therapeutics to patients.

Spinogenix, Inc., founded in 2016 and based in San Diego, California, specializes in developing neurorestorative therapeutics aimed at addressing neurodegenerative and psychiatric diseases. The company focuses on regenerating synapses to reverse declines in cognitive and motor function, seeking to create transformative treatments for conditions characterized by synaptic loss and dysfunction. Spinogenix aims to offer innovative drugs that restore brain connections affected by neurodegenerative diseases and brain injuries. Their approach involves directly modulating synaptic proteins, with the potential for their therapeutics to be used as standalone treatments or in combination with other therapies targeting specific degenerative processes.

Boston Immune Technologies & Therapeutics, Inc. is a biopharmaceutical company founded in 2011 and located in Winchester, Massachusetts. The company focuses on developing immune-based therapies for cancer and chronic infectious diseases. A key aspect of its research involves targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and addressing the specific population of TNFR2 regulatory T cells present in the tumor microenvironment. Through its innovative approaches, Boston Immune Technologies aims to advance immunotherapy options for patients facing these challenging health conditions.

Talus Bio is a biotech startup focused on drug discovery, particularly in the development of therapies targeting gene regulators for cancer treatment. The company utilizes a data-enabled platform that combines functional proteomics, automated biology, and machine learning to address the challenges associated with cancer transcription factors. Its proprietary MARMOT platform employs advanced techniques such as AI, quantitative proteomics, synthetic chemistry, and computational biology to design and analyze small-molecule drugs and proteins. This innovative approach aims to enhance drug development processes in the oncology sector, facilitating advancements in gene regulation and contributing to more effective cancer therapies.

Inherent Biosciences is a molecular diagnostics company focused on transforming the trial and error approach in medicine by leveraging insights from epigenetics. The company aims to provide clarity on complex health issues by identifying dysregulation across multiple genes and pathways, which informs personalized treatment strategies. Inherent Biosciences develops innovative therapies for a range of conditions, including pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. By translating biological discoveries into actionable insights, the company seeks to enhance patient care and improve outcomes in various medical fields.

Fesarius Therapeutics is a biotechnology company focused on developing modified skin replacement products through innovative tissue engineering technology. The company utilizes a proprietary method involving microspheres embedded in a collagen hydrogel, which enhances the interfaces that facilitate cell invasion into the scaffold. This approach aims to create engineered tissue products that support surgical repair of soft tissue defects, with potential applications in pelvic health, chronic wounds, and aesthetic reconstruction. By prioritizing cost-effective solutions, Fesarius Therapeutics seeks to enable patients to recover from trauma, burns, or infections effectively.

iMetabolic Biopharma Corporation is an early-stage precision medicine drug development company dedicated to addressing obesity-related diseases. The company aims to create first-in-class therapeutics for conditions that have significant unmet medical needs. Utilizing its iPlatform technology, iMetabolic Biopharma enhances the drug discovery process, providing both economic and time-saving benefits. This innovative approach is designed to expedite the development of life-saving solutions, enabling these therapeutics to reach clinical applications more quickly and affordably.

Access to Advanced Health Institute is a nonprofit biotech research institute that brings together specialists, technologies, and platforms to offer accessible goods and solutions for leveraging the immune system to alleviate disease.

AAVogen is a biotech startup that develops gene therapeutics for muscle wasting diseases. This includes muscular dystrophy, inflammatory myopathies and cancer cachexia. We make you stronger.

Opsin Biotherapeutics specializes in the development of gene therapies based on opsins, a class of light-sensitive proteins. The company's primary focus is to create a pipeline of treatments for pain management, aiming to provide effective alternatives to opioids.

Caeregen Therapeutics focuses on the development of innovative pharmacological therapies aimed at healing neurosensory diseases. The company’s primary goal is to repair, restore, and protect damaged neurosensory tissues by reactivating key biological pathways and signaling mechanisms associated with healthy cellular and tissue development. This approach enables the potential treatment of conditions such as retinal-related vision loss, providing patients with new options for recovery and improved quality of life. Through its commitment to regenerative medicine, Caeregen Therapeutics seeks to advance therapeutic solutions that address significant unmet medical needs in the field of neurosensory health.

Kintara Therapeutics, Inc. is a clinical-stage drug development company focused on creating and commercializing innovative anti-cancer therapies for patients with unmet medical needs. The company is advancing two late-stage therapeutics: VAL-083, a DNA-targeting agent designed to treat drug-resistant solid tumors such as glioblastoma multiforme and ovarian cancer, and REM-001, a photodynamic therapy aimed at cutaneous metastatic breast cancer. Kintara has established a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. for the manufacturing and sales of VAL-083 in China. Kintara Therapeutics was founded in 2009 and is headquartered in San Diego, California. The company seeks to address significant challenges faced by cancer patients who have not responded to conventional treatments.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company based in Houston, Texas, that focuses on developing and commercializing T cell-based immunotherapies and peptide-based vaccines for hematological malignancies and solid tumors. The company’s MultiTAA technology enhances the effectiveness of non-engineered tumor-specific T cells, enabling them to target multiple tumor-associated antigens simultaneously. This approach aims to prevent immune escape and foster durable immunity. Marker Therapeutics offers autologous T cell therapies for conditions such as lymphoma and multiple myeloma, while also developing allogeneic T cell therapies for acute myeloid leukemia and acute lymphoblastic leukemia. Additionally, the company is advancing peptide-based vaccines, including TPIV100/110 and TPIV200, which are currently in Phase II clinical trials for treating breast and ovarian cancers, respectively.

The University of Texas MD Anderson Cancer Center is a leading institution dedicated exclusively to cancer patient care, research, education, and prevention. Located in the Texas Medical Center in Houston, Texas, it was established as one of the original three comprehensive cancer centers under the National Cancer Act of 1971. MD Anderson serves as both a degree-granting academic institution and a specialized cancer treatment facility. It is affiliated with two prominent medical schools: The University of Texas Medical School at Houston and Baylor College of Medicine. Renowned for its exceptional cancer care, MD Anderson has consistently ranked among the top cancer hospitals in the United States, earning the No. 1 position in U.S. News & World Report's "Best Hospitals" survey for ten of the past twelve years. The center is widely recognized for its commitment to advancing cancer treatment and improving patient outcomes.

Shirley Ryan AbilityLab is a translational research hospital. Their services include spinal cord injury recovery, brain injury recovery, COVID recovery, pediatric and adolescent rehabilitation, nursing, cancer rehabilitation, limb loss and impairment, and pain management.

Aphios Corporation is a biotechnology company based in Woburn, Massachusetts, specializing in drug delivery and manufacturing technologies. Founded in 1993, Aphios develops innovative platforms that enhance drug discovery and ensure the safety of pharmaceuticals. The company focuses on creating therapeutic products aimed at health maintenance, disease prevention, and treatment of various conditions, including cancers, infectious diseases, and central nervous system disorders. Notable products include Zindol, a ginger-derived therapeutic, and several advanced formulations such as APH-0703, a protein kinase C activator, and APH-0911, a nanotechnology-based prodrug for cancer treatment. Additionally, Aphios is engaged in developing technologies related to supercritical fluids for the production of natural pharmaceuticals, as well as specialized equipment for various applications, including microbial cell disruption and biomass pretreatment for biofuels. The company also provides virology testing services to validate viral clearance and inactivation.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supply, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candiate has been shown in mouse models to reduce primary tumor growth, inhibit metastases, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). Importantly, the agents are well tolerated and can be combined with therapeutics that work in well oxygenated regions of cancers, leading to dramatically enhanced cancer control.

Montefiore Health System offers advanced specialty programs, cardiology, and cardiac surgery. They provide cancer care, children’s health, tissue, and organ transplantation. Their services include women’s health, surgery, and surgical subspecialties. If anyone wants to contact them please contact them via phone call or email.

Dignify Therapeutics LLC is a drug development company based in Durham, North Carolina, that focuses on creating innovative pharmaceutical agents aimed at restoring voluntary control of bladder and bowel functions in patients with spinal cord injuries, spina bifida, multiple sclerosis, and other neurological conditions. Founded in 2013, the company combines novel drug therapies with advanced drug delivery technologies to enhance the quality of life for individuals affected by these disorders. By targeting the specific needs of this patient population, Dignify Therapeutics aims to redefine treatment options and provide effective solutions that enable patients to regain dignity in their excretory functions.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies aimed at treating inflammatory neurological and retinal diseases. The company leverages insights from research that highlights the role of fibrin in driving chronic innate immune activation, which is implicated in various human diseases with significant unmet medical needs. Currently, Therini Bio is working on therapeutics that aim to protect the nervous system from damage associated with conditions such as multiple sclerosis. By developing specialized antibodies for neuroinflammatory diseases linked to vascular dysfunction, the company seeks to provide healthcare providers with effective treatment options that can improve patient outcomes.

Is my medication working? Levl helps you reveal the answer. Levl measures the effectiveness of medications and offers insights to get the most out of mental health treatments. Levl helps people stick to their treatment while supporting clinicians in optimizing the medication.

Actuated Medical, Inc. engages in outsourced research and development, designing and modeling, prototyping, and manufacturing medical devices. It offers occlusion clearing systems, such as NG-Clear for removing and disintegrating nasogastric (NG) tube clogs; and PEG-Clear for clearing and breaking up percutaneous endoscopic gastrostomy (PEG) tube clogs. The company also provides controlled tissue penetration systems, including resonance assisted insertion lancets for humane blood sampling of research subjects; low insertion force epidural systems for the entry of epidural needles; and resonance assisted vascular entry needles for aiding in vascular access for compromised and difficult access patients. In addition, Actuated Medical, Inc. offers magnetic resonance imaging compatible systems, such as direct drive motor for improving patient care by enabling various diagnostic and surgical procedures to be performed during MRI imaging; and transdermal patches for administering long-term and controlled-delivery medications subcutaneously. The company was formerly known as Piezo Resonance Innovations, Inc. and changed its name to Actuated Medical, Inc. in September 2011. Actuated Medical, Inc. was founded in 2006 and is based in Bellefonte, Pennsylvania.

BIOS Health is a pioneering company focused on developing neural digital therapies by leveraging data from the human nervous system. By identifying neural biomarkers that correlate nerve activity to specific medical conditions, BIOS aims to revolutionize precision medicine. Their research offers the potential for innovative treatments for a range of chronic diseases, including hypertension, diabetes, and neurodegenerative disorders such as Parkinson's and Alzheimer's. Co-founded by experts from Cambridge University, the team includes professionals from diverse fields such as neuroscience, machine learning, and biotechnology. Additionally, BIOS is working on prosthetic connectors that standardize connections between bionic devices and neural systems, facilitating neural control and feedback for amputees. This dual approach positions BIOS at the forefront of improving the quality of life for individuals with chronic conditions and those requiring prosthetic solutions.

Ria Health is an online platform that provides telehealth services for individuals looking to improve their relationship with alcohol. It offers personalized treatment plans that include medication-assisted treatment options and behavioral therapies, all supported by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability in their recovery journey. Ria Health features a mobile app that grants users access to educational materials, support groups, and direct communication with care teams. This comprehensive approach aims to assist individuals in managing alcohol consumption and fostering healthier habits.

Aptinyx Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for brain and nervous system disorders. Founded in 2015 and based in Evanston, Illinois, the company focuses on novel, synthetic small molecules that modulate the NMDA receptor, enhancing communication pathways between nerve cells. Its primary products in development include NYX-2925, which is undergoing Phase II trials for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, Aptinyx is developing NYX-458, another NMDA receptor modulator, which is in Phase I clinical studies aimed at treating cognitive impairment associated with Parkinson’s disease. The company also collaborates with Allergan to develop compounds for major depressive disorder, underscoring its commitment to addressing significant unmet medical needs in the central nervous system arena.

Cellular Logistics, Inc. is a biotechnology company founded in 2016 and based in Madison, Wisconsin. The company specializes in developing an acellular biomaterial that serves as a stand-alone therapeutic for cardiac and tissue vascularization applications. This innovative biomaterial aims to significantly enhance cell survival rates and retention in regenerative medicine therapeutics. It also functions as a delivery mechanism for these therapies, improving post-injection cell retention and ultimately benefiting patients undergoing regenerative treatments.

Neurovations, a patient care and innovation company, was founded in 1992 by CEO Dr. Eric Grigsby. Today, Neurovations is a national leader in medical device and pharmaceutical innovation, clinical research, and a world-class education program focusing in pain and neuroscience. Dr. Grigsby is deeply connected to the healthcare community through our non-profit HealthRoots Foundation. Our unwavering mission is to inspire hope and to contribute to the health and well-being of our patients and communities through integrated clinical practice, research, and education.

Whitman-Walker Health provides health and wellness services. They provide HIV, prep, pep, medical and community care, insurance navigation services, gender affirming care and services, youth and family support, legal services, dental health, and behavorial health services.

Efemoral Medical is a medical technology company focused on creating durable, minimally invasive treatment solutions for patients with peripheral vascular disease. The company's flagship product, the Efemoral Vascular Scaffold System (EVSS) featuring FlexStep Technology, aims to improve treatment strategies for peripheral artery disease (PAD) interventions. This innovative technology includes a bioresorbable intravascular stent designed to maintain or enhance the patency of blood vessels, specifically in peripheral locations, thereby enabling healthcare providers to deliver effective treatments for patients suffering from this condition.

We are a women's owned startup focusing on new therapeutic approaches to gynecological conditions. Our primary focus is endometriosis. We approach endometriosis with a holistic view and our therapies focus on the stress system rather that on the reproductive system.

Unlocked Labs specializes in developing innovative probiotics aimed at addressing chronic health conditions by utilizing genetically optimized microbial strains. The company focuses on activating dormant microbial abilities to effectively digest compounds that can lead to health issues. Their first product targets the risk of kidney stones by breaking down stone-forming compounds derived from healthy foods like leafy vegetables. Unlocked Labs employs alternative regulatory pathways to expedite the availability of safe and effective probiotic solutions for consumers. By harnessing the natural detoxifying capabilities of symbiotic microbes, their products aim to reduce acid levels in the body, making them both affordable and accessible to a wide audience.

Evaxion Biotech A/S is a clinical-stage biotechnology company focused on utilizing artificial intelligence to decode the human immune system and develop innovative immunotherapies for cancer and infectious diseases. The company leverages its proprietary AI-immunology technology to create a diverse pipeline of product candidates, which includes three patient-specific cancer immunotherapies—two of which are in Phase I/IIa clinical trials. In addition to its cancer treatments, Evaxion is also advancing a portfolio of vaccines aimed at preventing bacterial and viral infections, with one program targeting Methicillin-resistant Staphylococcus aureus currently in preclinical development. By combining AI with immunology, Evaxion seeks to improve therapeutic efficacy for patients with unmet medical needs.

AAVogen is a biotech startup that develops gene therapeutics for muscle wasting diseases. This includes muscular dystrophy, inflammatory myopathies and cancer cachexia. We make you stronger.

iQure Pharma is a global biotech company dedicated to developing innovative therapeutics for neurodegenerative diseases, particularly focusing on epilepsy. Founded by entrepreneurs and former pharmaceutical managers, the company aims to address unmet medical needs by creating new chemical entities with unique modes of action. This approach allows for the exploration of novel medical therapies, including options for patients who are resistant to existing treatments. By concentrating on these challenging conditions, iQure Pharma seeks to improve outcomes for individuals affected by epilepsy and other related disorders.

Pantherics is a new type of therapy based on modulation of peripheral GABAA receptors.

Immuto Scientific is a biotechnology services company that specializes in providing analytical insights to pharmaceutical firms involved in drug discovery. The company has developed a protein footprinting technology that automates complex protein analysis, significantly enhancing the efficiency of the drug development process for protein therapeutics. This technology offers a faster alternative to traditional methods for protein structure analysis, allowing drug developers to determine protein structures more quickly and effectively, thereby streamlining the overall drug discovery process.

Oligomerix, Inc. is a biopharmaceutical company based in Bronx, New York, founded in 2006. It specializes in developing therapeutics for Alzheimer’s disease and related neurodegenerative disorders through innovative research on tau proteins. The company focuses on small molecule drug discovery, specifically targeting tau oligomers and developing tau protease inhibitors. In addition to small molecules, Oligomerix is involved in creating antibody fragments that serve as biomarkers to aid in drug development, diagnostics, and therapeutic applications. By leveraging its novel approaches to generate stable amyloid oligomers, Oligomerix aims to enhance target identification and validation, contributing to improved treatment options for various tauopathies, including progressive supranuclear palsy and frontotemporal dementia.

Eliaz Therapeutics has developed a patented medical device that selectively removes galectin-3 from human blood, addressing currently untreatable life-threatening diseases. This device targets galectin-3, a protein associated with conditions such as diabetes, chronic kidney disease, organ fibrosis, and cancer. By employing a single-use apheresis column that utilizes a proprietary capturing molecule, the device effectively eliminates both bound and free galectin-3 from circulation. This innovative approach offers a less invasive treatment option with fewer side effects compared to traditional therapies, enabling physicians to provide effective care for patients suffering from acute kidney injury, sepsis, and other inflammatory and fibrotic diseases. The device is designed for easy integration into existing hospital practices, enhancing its potential for widespread adoption.

Reliant Glycosciences is a biotechnology company dedicated to the development of diagnostic and prognostic tools aimed at patients with IgA nephropathy. The company specializes in creating assays that identify biomarkers associated with this condition, which offer both diagnostic and prognostic insights. By characterizing these disease-specific biomarkers, Reliant Glycosciences supports the development and testing of targeted therapies for IgA nephropathy, ultimately aiding in the advancement of transformative treatment options for affected individuals.

Immunicom, Inc. is a clinical research company based in San Diego, California, founded in 2013. The company focuses on innovative, non-pharmaceutical approaches to immunotherapy, specifically targeting cancer, inflammatory diseases, and autoimmune disorders. Its flagship product is a therapeutic blood-filtering device designed to treat various types of cancer, including those resistant to traditional treatments. This device aims to enhance the effectiveness of existing cancer therapies while potentially reducing side effects, thus providing physicians with a new tool to directly combat cancer. By redefining the boundaries of immunotherapy, Immunicom seeks to improve treatment options for patients with terminal diseases.

Talus Bio is a biotech startup focused on drug discovery, particularly in the development of therapies targeting gene regulators for cancer treatment. The company utilizes a data-enabled platform that combines functional proteomics, automated biology, and machine learning to address the challenges associated with cancer transcription factors. Its proprietary MARMOT platform employs advanced techniques such as AI, quantitative proteomics, synthetic chemistry, and computational biology to design and analyze small-molecule drugs and proteins. This innovative approach aims to enhance drug development processes in the oncology sector, facilitating advancements in gene regulation and contributing to more effective cancer therapies.

NovoMedix is a biotechnology company focused on developing novel orally available small molecules aimed at treating fibrotic disorders and certain cancers, particularly triple negative breast cancer (TNBC). The company’s innovative compounds demonstrate significant efficacy in animal models for fibrosis and possess unique properties that offer cardioprotective effects in conjunction with standard chemotherapy treatments. This is especially relevant for TNBC patients who often experience delayed cardiomyopathy as a result of anthracycline treatments, which can lead to cardiovascular disease being a leading cause of death among breast cancer survivors. By co-targeting pathways involved in both cancer treatment and heart protection, NovoMedix aims to enhance patient responses to therapy while significantly reducing the risk of cardiotoxicity. The company is preparing to initiate IND enabling studies for its lead candidate, with the goal of delivering this promising therapy to TNBC patients as quickly as possible.

Meridian Bioscience is an integrated life science company that develops, manufactures, and distributes clinical diagnostic test kits for gastrointestinal, viral, respiratory, and parasitic infectious diseases. The company specializes in molecular and immunological reagents, providing tools that support the discovery and diagnosis of various medical conditions. In addition to diagnostic test kits, Meridian offers bulk antigens, antibodies, PCR and qPCR reagents, nucleotides, and bioresearch reagents, serving researchers and other diagnostic manufacturers. Moreover, the company engages in contract development and manufacturing of proteins and other biologicals under cGMP conditions, catering to biopharmaceutical and biotechnology firms involved in drug and vaccine research. Meridian operates through three segments: U.S. Diagnostics, European Diagnostics, and Life Science, emphasizing its commitment to enhancing healthcare outcomes through innovative solutions.

Novoron Bioscience, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative treatments for various central nervous system (CNS) disorders, including multiple sclerosis, spinal cord injury, glaucoma, and stroke. Founded in 2013, the company specializes in creating therapeutic approaches that target neurological damage and diseases using novel science centered on lipoprotein receptors. Novoron is advancing a pipeline of pre-clinical therapies aimed at addressing conditions such as Alzheimer's disease, tauopathies, and demyelinating diseases, with the goal of offering effective treatments for conditions that currently lack viable options. The company's research emphasizes repairing damage to the brain and spinal cord, ultimately striving to enhance recovery for patients suffering from debilitating neurological conditions.

Mi-Helper helps to develop a non-drug remedy for migraine and mood issues.

Delpor, Inc. is engaged in the development of innovative drug delivery technologies that facilitate the sustained or pattern-specific release of proteins, peptides, and small molecules via a small non-mechanical subcutaneous implant. The company offers several technologies, including Prozor, which delivers antipsychotics and other small molecule drugs, and NANOPOR, designed for sustained release through specialized membrane architecture. Additionally, Delpor has developed the Delos PUMP, a self-contained device that allows for the pulsed delivery of medications at programmed intervals, benefiting treatments such as hormones for fertility, diabetes management, and pain relief. Founded in 2009 and located in San Francisco, California, Delpor aims to enhance medication adherence and patient convenience by providing an alternative to frequent injections through its implantable solutions.

4E Therapeutics is focused on developing innovative therapies for chronic pain disorders, particularly neuropathic pain, which represents a significant unmet medical need. The company specializes in creating orally bioavailable MNK inhibitors that exhibit enhanced tissue-specificity and pharmacokinetic profiles. These compounds are designed to effectively target and regulate the activity of pain-sensing neurons in the peripheral nervous system. In addition to neuropathic pain, 4E Therapeutics is also engaged in the discovery and development of treatments for migraine and acute pain, leveraging their expertise in analgesic activity demonstrated through multiple animal pain models.

InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Their lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). They are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cell and gene therapies aimed at treating hematologic cancers, solid tumors, and rare genetic diseases. The company has a diverse pipeline that includes gene therapy programs for rare genetic disorders and various chimeric antigen receptor (CAR) T cell therapies targeting both hematologic malignancies and solid tumors. Notable projects include MB-107, a gene therapy aimed at treating X-linked severe combined immunodeficiency, which is currently undergoing Phase 1/2 clinical trials. Other therapies under development include MB-102 for acute myeloid leukemia, MB-106 for B-cell lymphomas, and multiple CAR T programs targeting glioblastoma, prostate cancer, and pancreatic cancer. Mustang Bio also collaborates with institutions such as Nationwide Children’s Hospital and Beth Israel Deaconess Medical Center for research and development in gene editing and oncolytic viruses. Established in 2015 and headquartered in New York, Mustang Bio operates as a subsidiary of Fortress Biotech, Inc.

Amplo Biotechnology is focused on developing innovative Adeno-Associated Viral (AAV) therapies aimed at addressing severe diseases related to the neuromuscular junction, which can lead to paralysis, breathing difficulties, and swallowing challenges. The company targets conditions such as congenital myasthenic syndromes, leveraging its lead program, AAV-Dok7, developed by a research group at the University of Tokyo. The therapies are administered through intravascular injections, initiating molecular processes that enable effective treatment for patients suffering from these rare disorders. Amplo’s mission is to create potentially curative solutions for conditions that significantly impact patient health and quality of life.

Benten Technologies is a social impact company dedicated to democratizing healthcare. The organization has secured approximately $9 million in non-dilutive funding to develop a pipeline of digital therapeutics aimed at making healthcare services more accessible. In addition to its healthcare initiatives, Benten Technologies also provides technology consulting services, which encompass application development, management consulting, quality assurance, and research and development. By leveraging proven system integration methodologies and expertise, the company enables organizations to deliver effective, value-driven business solutions.

Partillion Bioscience is an early-stage life science company focused on developing a functional single-cell analysis platform. This innovative platform utilizes a novel nano vial technology to rapidly compartmentalize and analyze millions of single cells, specifically targeting secreted proteins. By enabling detailed examination of biological functions, Partillion aims to democratize advanced single-cell assays for biotech laboratories and clients. This capability supports the development of more effective therapies for various conditions, including cancer, autoimmune diseases, and infectious diseases.

Vibrato Medical is focused on developing a noninvasive therapeutic ultrasound device aimed at treating Critical Limb Ischemia and Peripheral Arterial Disease. This innovative technology is designed to enhance tissue perfusion, alleviate symptoms, and prevent limb loss by promoting vasodilation and vessel growth. Drawing on extensive research and the latest advancements in ultrasound technology, Vibrato Medical's device is the first of its kind that can be worn and used conveniently at home without the need for surgical incisions. This approach offers patients an accessible and effective option for managing their conditions.

Nanoscope Therapeutics Inc. specializes in developing innovative gene therapies aimed at restoring vision for individuals suffering from retinal degenerative diseases, including retinitis pigmentosa and dry age-related macular degeneration. Founded in 2017 and based in Bedford, Texas, the company employs light-sensitive molecules and light-assisted gene delivery techniques to target and treat specific areas of the retina. This approach allows for the re-sensitization of retinal cells to low light levels, enabling patients to regain some degree of vision. Nanoscope's therapeutic platform focuses on providing effective solutions for vision loss, addressing a significant unmet need in the field of ocular health.

Novoron Bioscience, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative treatments for various central nervous system (CNS) disorders, including multiple sclerosis, spinal cord injury, glaucoma, and stroke. Founded in 2013, the company specializes in creating therapeutic approaches that target neurological damage and diseases using novel science centered on lipoprotein receptors. Novoron is advancing a pipeline of pre-clinical therapies aimed at addressing conditions such as Alzheimer's disease, tauopathies, and demyelinating diseases, with the goal of offering effective treatments for conditions that currently lack viable options. The company's research emphasizes repairing damage to the brain and spinal cord, ultimately striving to enhance recovery for patients suffering from debilitating neurological conditions.

Omnix Medical is a clinical-stage biopharmaceutical company focused on developing and commercializing effective antibiotic agents to combat resistant pathogenic bacterial strains. As antimicrobial resistance becomes an increasingly critical public health issue, Omnix aims to address the growing number of infections caused by multi-drug resistant bacteria. By leveraging innovative technology, the company seeks to create antibiotics that can provide effective treatments for life-threatening infections, ultimately improving outcomes for patients affected by these resistant infections. Through its efforts, Omnix Medical is committed to enhancing public health and offering solutions to a significant global challenge.

Praxis Bioresearch is a privately-held biopharmaceutical company focused on the discovery and development of innovative prodrug stimulants aimed at treating various chronic neuropsychiatric and neurodegenerative disorders. The company's lead candidate, PRX-P4-003, is designed to provide the therapeutic benefits associated with existing stimulant medications while minimizing the risk of intravenous abuse. Through its research and development efforts, Praxis Bioresearch seeks to address unmet medical needs in the management of these complex conditions.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

Cytonus Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Columbus, Ohio. The company focuses on developing immune-oncology and gene therapies aimed at treating devastating and rare diseases. Cytonus combines artificial intelligence-driven drug discovery with a unique delivery system known as Cargocyte, which utilizes synthetic biology for precision treatment. The company's mission centers on addressing immune-related disorders through innovative approaches that enable targeted delivery and in vivo production of first-in-class therapeutics.

Partillion Bioscience is an early-stage life science company focused on developing a functional single-cell analysis platform. This innovative platform utilizes a novel nano vial technology to rapidly compartmentalize and analyze millions of single cells, specifically targeting secreted proteins. By enabling detailed examination of biological functions, Partillion aims to democratize advanced single-cell assays for biotech laboratories and clients. This capability supports the development of more effective therapies for various conditions, including cancer, autoimmune diseases, and infectious diseases.

AvantGen is a biotechnology company based in San Diego, established in 2006, that specializes in therapeutic antibody discovery and optimization. The company operates two divisions: Therapeutic and Research & Diagnostic. Its Therapeutic Division focuses on the discovery of novel human antibodies, antibody humanization, and affinity maturation to enhance therapeutic development. AvantGen utilizes a proprietary yeast display system and maintains a large natural human antibody database, along with fully human antibody libraries and advanced screening technologies. The company's innovative platform also includes methodologies for rabbit monoclonal antibody generation and cell engager technology. AvantGen collaborates with pharmaceutical and biotechnology firms, offering services and licensing agreements to expedite the development of antibody-based therapeutics.

HDT Bio is a clinical-stage biotechnology company focused on developing RNA vaccines and therapeutics to combat infectious diseases and cancer. Utilizing its innovative LION formulation technology, the company creates ribonucleic acid-based products that enhance the delivery and stability of nucleic acids through various administration routes. HDT Bio’s offerings include self-amplifying RNA vaccines and innate immune agonist therapeutics, which aim to activate innate immunity, amplify adaptive immune responses, and disrupt tumor tight junctions. The company's mission is to advance immunotherapy technologies in a cost-effective manner, addressing critical healthcare needs in both developed and low- to middle-income countries, particularly in the fight against some of the world's most dangerous infectious diseases.

Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas, focused on developing innovative treatments and diagnostic tools for nervous system disorders, particularly Alzheimer's disease. The company's lead therapeutic candidate, simufilam, is undergoing Phase 3 clinical trials to assess its efficacy in treating Alzheimer's disease dementia. Additionally, Cassava is advancing SavaDx, a blood-based diagnostic aimed at detecting Alzheimer's disease early, potentially years before symptoms manifest. Founded in 1998 and originally known as Pain Therapeutics, Inc., Cassava Sciences has shifted its focus to neuroscience, leveraging scientific insights to address the complex challenges associated with neurological conditions.